Mark Crowther

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9568420/publications.pdf

Version: 2024-02-01

185 papers	26,233 citations	20759 60 h-index	6113 159 g-index
193 all docs	193 docs citations	193 times ranked	20269 citing authors

#	Article	IF	Citations
1	Ketamine administration for acute painful sickle cell crisis: AÂrandomized controlled trial. Academic Emergency Medicine, 2022, 29, 150-158.	0.8	19
2	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thrombosis and Haemostasis, 2022, 122, 998-1005.	1.8	19
3	Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review. Thrombosis Research, 2022, 213, 16-26.	0.8	1
4	Iron chelation therapy in patients with lowâ€•to intermediateâ€•risk myelodysplastic syndrome: A systematic review and metaâ€•analysis. British Journal of Haematology, 2022, 197, .	1.2	5
5	Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12724.	1.0	3
6	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. British Journal of Anaesthesia, 2021, 126, 163-171.	1.5	29
7	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. British Journal of Anaesthesia, 2021, 126, 172-180.	1.5	8
8	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. Critical Reviews in Oncology/Hematology, 2021, 157, 103125.	2.0	11
9	Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020. International Journal of Stroke, 2021, 16, 321-341.	2.9	64
10	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Critical Care Medicine, 2021, 49, e219-e234.	0.4	289
11	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis, 2021, 121, 1097-1106.	1.8	14
12	Double Blind Pilot Randomized Trial Comparing Extended Anticoagulation to Placebo Following Major Lung Resection for Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 1123-1134.	0.4	5
13	Iron supplementation following bariatric surgery: A systematic review of current strategies. Obesity Reviews, 2021, 22, e13268.	3.1	4
14	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke, 2021, 52, 2096-2105.	1.0	25
15	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs â€“ A Systematic Review and Meta-analysis. TH Open, 2021, 05, e438-e448.	0.7	7
16	Reducedâ€•dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: A systematic review and metaâ€•analysisâ€”Response to Commentary. Journal of Thrombosis and Haemostasis, 2021, 19, 2359-2360.	1.9	4
17	Equity and game theory strategies to promote gender diversity and inclusion in an academic health science center. CJC Open, 2021, 3, S53-S61.	0.7	2
18	A systematic review of the association between anti-Î²-2 glycoprotein I antibodies and APS manifestations. Blood Advances, 2021, 5, 3931-3936.	2.5	15

#	Article	IF	Citations
19	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	0
20	Iron Chelation Therapy in Low- to Intermediate- Risk Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4661-4661.	0.6	0
21	Thrombotic Events in COVID-19 Patients Undergoing Convalescent Plasma Therapy: A Systematic Review. Blood, 2021, 138, 3221-3221.	0.6	0
22	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Current Oncology, 2021, 28, 5434-5451.	0.9	26
23	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology,the, 2020, 7, e18-e27.	2.2	173
24	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urineâ€"A Multicenter Trial. Thrombosis and Haemostasis, 2020, 120, 132-140.	1.8	30
25	Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thrombosis Research, 2020, 194, 240-245.	0.8	43
26	GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology, 2020, 122, 142-152.	2.4	167
27	Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study. Blood Advances, 2020, 4, 5373-5377.	2.5	60
28	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2126-2137.	1.9	84
29	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology,the, 2020, 7, e746-e755.	2.2	21
30	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Medical Research Methodology, 2020, 20, 113.	1.4	37
31	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2274-2286.	1.9	24
32	The value of bleeding scores in the assessment of patients presenting with bleeding of unknown cause: Complex algorithms with little predictive value. European Journal of Internal Medicine, 2020, 78, 26-27.	1.0	2
33	Evaluating the quality of systematic reviews and meta-analyses published on direct oral anticoagulants in the past 5 years. BMJ Evidence-Based Medicine, 2020, , bmjebm-2019-111326.	1.7	1
34	Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). Blood Advances, 2020, 4, 2460-2467.	2.5	7
35	Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2308-2317.	1.9	10
36	Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. Hematology, 2020, 25, 112-117.	0.7	10

#	Article	IF	Citations
37	Fibrin and Thrombin Sealants in Vascular and Cardiac Surgery: A Systematic Review and Meta-analysis. European Journal of Vascular and Endovascular Surgery, 2020, 60, 469-478.	0.8	16
38	GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology, 2020, 122, 129-141.	2.4	168
39	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood, 2020, 135, 239-251.	0.6	145
40	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
41	A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Advances, 2020, 4, 728-739.	2.5	25
42	The risk of major bleeding in patients with suspected heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 1956-1965.	1.9	42
43	North America anticoagulation forum guidance on reversal of direct oral anticoagulants. European Journal of Internal Medicine, 2019, 67, 30-32.	1.0	4
44	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. JAMA - Journal of the American Medical Association, 2019, 322, 1966.	3.8	106
45	Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thrombosis Research, 2019, 184, 16-23.	0.8	18
46	Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy. JAMA - Journal of the American Medical Association, 2019, 321, 1993.	3.8	221
47	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. American Journal of Hematology, 2019, 94, 697-709.	2.0	225
48	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	13.9	687
49	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thrombosis Research, 2019, 184, 58-61.	0.8	14
50	Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial. Blood, 2019, 134, 3685-3685.	0.6	8
51	Case Report: Two Cases of Strongyloidiasis Presenting with Thrombotic Events. American Journal of Tropical Medicine and Hygiene, 2019, 101, 418-421.	0.6	5
52	Evaluating the Quality of Systematic Reviews & Meta-Analyses Published on Direct Oral Anticoagulants in the Past 5 Years. Blood, 2019, 134, 5802-5802.	0.6	0
53	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. Blood, 2019, 134, 711-711.	0.6	1
54	Severe coagulopathy after a massasauga rattlesnake bite. Cmaj, 2018, 190, E191-E194.	0.9	3

#	Article	IF	Citations
55	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine, 2018, 378, 699-707.	13.9	294
56	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thrombosis and Haemostasis, 2018, 118, 842-851.	1.8	157
57	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2018, 45, 578-587.	1.0	0
58	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thrombosis Research, 2018, 162, 104-109.	0.8	27
59	The risk of venous thromboembolism in patients with clinically overt gastrointestinal bleeding. American Journal of Hematology, 2018, 93, E42-E45.	2.0	1
60	Andexanet alfa for the treatment of hemorrhage. Expert Review of Hematology, 2018, 11, 847-855.	1.0	5
61	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3155-3162.	2.5	38
62	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900.	0.8	15
63	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. European Journal of Haematology, 2018, 101, 362-367.	1.1	5
64	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. Blood, 2018, 132, 2518-2518.	0.6	0
65	Mortality outcomes in patients transfused with fresher versus older red blood cells: a metaâ€analysis. Vox Sanguinis, 2017, 112, 268-278.	0.7	43
66	Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1322-1333.	1.9	67
67	Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ: British Medical Journal, 2017, 357, j2216.	2.4	15
68	Autoantibodies against the cell surfaceâ€"associated chaperone GRP78 stimulate tumor growth via tissue factor. Journal of Biological Chemistry, 2017, 292, 21180-21192.	1.6	17
69	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology,the, 2017, 4, e544-e552.	2.2	34
70	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. CMAJ Open, 2017, 5, E594-E603.	1.1	6
71	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thrombosis Research, 2017, 160, 97-104.	0.8	18
72	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. Chest, 2017, 151, 127-138.	0.4	245

#	Article	IF	Citations
73	The direct oral anticoagulants: can we finally stop using rat poison?. Blood Advances, 2017, 1, 980-980.	2.5	0
74	Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature. Case Reports in Hematology, 2017, 2017, 1-11.	0.3	17
75	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Advances, 2017, 1, 1827-1838.	2.5	50
76	Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. Journal of Thoracic Disease, 2017, 9, 80-87.	0.6	25
77	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. , 2017, , 223-233.		6
78	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. Thrombosis and Haemostasis, 2016, 116, 480-485.	1.8	7
79	Rapid quantitative Dâ€dimer to exclude pulmonary embolism: a prospective cohort management study. Journal of Thrombosis and Haemostasis, 2016, 14, 504-509.	1.9	25
80	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. European Journal of Epidemiology, 2016, 31, 541-561.	2.5	21
81	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	0.8	18
82	Andexanet Alfa for Factor Xa Inhibitor Reversal. New England Journal of Medicine, 2016, 375, 2498-2500.	13.9	22
83	Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology American Society of Hematology Education Program, 2016, 2016, 188-195.	0.9	37
84	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. Seminars in Thrombosis and Hemostasis, 2016, 42, 671-681.	1.5	7
85	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. American Journal of Medicine, 2016, 129, e247-e248.	0.6	13
86	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	13.9	692
87	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. Thrombosis and Haemostasis, 2016, 116, 879-890.	1.8	139
88	A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. BMC Hematology, 2016, 16, 17.	2.6	5
89	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 32-67.	1.0	243
90	Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our Preconceptions. Journal of General Internal Medicine, 2016, 31, 147-148.	1.3	3

#	Article	IF	Citations
91	Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With RecurrentClostridium difficileInfection. JAMA - Journal of the American Medical Association, 2016, 315, 142.	3.8	511
92	Postdischarge venous thromboembolic complications following pulmonary oncologic resection: An underdetected problem. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 992-999.	0.4	40
93	Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of Crcl <30 Ml/Min from the Trivet Study. Blood, 2016, 128, 90-90.	0.6	4
94	Modified Early Warning Score (MEWS) Identifies Critical Illness among Ward Patients in a Resource Restricted Setting in Kampala, Uganda: A Prospective Observational Study. PLoS ONE, 2016, 11, e0151408.	1.1	69
95	Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis. Blood, 2016, 128, 88-88.	0.6	0
96	Antidotes for Novel Oral Anticoagulants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1736-1745.	1.1	114
97	Venous Thromboembolism Prophylaxis in Critically Ill Patients. Seminars in Thrombosis and Hemostasis, 2015, 41, 068-074.	1.5	50
98	Aspirin in secondary prevention of recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2015, 39, 392-394.	1.0	6
99	Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. Annals of Pharmacotherapy, 2015, 49, 125-126.	0.9	0
100	Systematic review of anticoagulant treatment of catheter-related thrombosis. Thrombosis Research, 2015, 136, 1103-1109.	0.8	28
101	The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfusion, 2015, 13, 559-68.	0.3	78
102	Portal Vein Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 498-506.	0.7	32
103	Comment on: Editorial by Husted et al. â€œNon-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novelâ€• Thrombosis and Haemostasis, 2014, 112, 841-841.	1.8	6
104	Laboratory Measurement of the Anticoagulant Activity of the Nonâ€“VitaminÂK Oral Anticoagulants. Journal of the American College of Cardiology, 2014, 64, 1128-1139.	1.2	414
105	Heparin-induced thrombocytopenia in the critically ill: Interpreting the 4Ts test in a randomized trial. Journal of Critical Care, 2014, 29, 470.e7-470.e15.	1.0	44
106	Myocardial Injury after Noncardiac Surgery. Anesthesiology, 2014, 120, 564-578.	1.3	740
107	Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit. Critical Care, 2014, 18, R82.	2.5	23
108	The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood, 2014, 124, 2450-2458.	0.6	290

#	Article	IF	Citations
109	The thrombogenicity of C1 esterase inhibitor (human): Review of the evidence. Allergy and Asthma Proceedings, 2014, 35, 444-453.	1.0	31
110	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. Blood, 2014, 124, 4269-4269.	0.6	75
111	Reversal of target-specific oral anticoagulants. Journal of Thrombosis and Thrombolysis, 2013, 36, 195-202.	1.0	36
112	Antithrombotic Agents. , 2013, , 477-495.		2
113	Thrombosis. , 2013, , 67-77.		1
114	Phase 4 research: what happens when the rubber meets the road?. Hematology American Society of Hematology Education Program, 2013, 2013, 15-18.	0.9	13
115	Indications, Complications, and Management of Inferior Vena Cava Filters. JAMA Internal Medicine, 2013, 173, 513.	2.6	209
116	Non-OO blood type influences the risk of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 1172-1179.	1.8	44
117	American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response. Chest, 2013, 143, 1191.	0.4	1
118	Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis. Chest, 2013, 144, 1207-1215.	0.4	171
119	Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness. Chest, 2013, 144, 848-858.	0.4	60
120	Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. Annals of Internal Medicine, 2013, 158, 800.	2.0	176
121	Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit. Evidence-Based Medicine, 2012, 17, 154-155.	0.6	0
122	Approaches to Diagnosing and Managing Anticoagulant-Related Bleeding. Seminars in Thrombosis and Hemostasis, 2012, 38, 702-710.	1.5	14
123	Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. Circulation, 2012, 126, 2381-2391.	1.6	359
124	Diagnosis of DVT. Chest, 2012, 141, e351S-e418S.	0.4	570
125	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 2012, 119, 1356-1362.	0.6	111
126	Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. Journal of Thrombosis and Haemostasis, 2012, 10, 1830-1840.	1.9	89

#	Article	IF	Citations
127	Antithrombotic Therapy for VTE Disease. Chest, 2012, 141, e419S-e496S.	0.4	3,745
128	Newer Anticoagulants in Critically Ill Patients. Critical Care Clinics, 2012, 28, 427-451.	1.0	7
129	Oral Anticoagulant Therapy. Chest, 2012, 141, e44S-e88S.	0.4	1,323
130	Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest, 2012, 141, e495S-e530S.	0.4	860
131	Executive Summary. Chest, 2012, 141, 7S-47S.	0.4	1,452
132	Introduction to the Ninth Edition. Chest, 2012, 141, 48S-52S.	0.4	129
133	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Chest, 2012, 141, 53S-70S.	0.4	213
134	Evidence-Based Management of Anticoagulant Therapy. Chest, 2012, 141, e152S-e184S.	0.4	1,105
135	Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. American Journal of Hematology, 2012, 87, S141-5.	2.0	320
136	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20â€“21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	1.0	0
137	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thrombosis and Haemostasis, 2011, 106, 429-438.	1.8	295
138	Treatment of warfarin-associated coagulopathy with vitamin K. Expert Review of Hematology, 2011, 4, 657-667.	1.0	37
139	Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism. British Journal of Haematology, 2011, 155, 511-513.	1.2	4
140	Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. Journal of Thrombosis and Thrombolysis, 2011, 31, 249-258.	1.0	40
141	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14â€“16, 2010, SÃ£o Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	1.0	2
142	Dalteparin versus Unfractionated Heparin in Critically Ill Patients. New England Journal of Medicine, 2011, 364, 1305-1314.	13.9	382
143	Intensity of Warfarin Coagulation in the Antiphospholipid Syndrome. Current Rheumatology Reports, 2010, 12, 64-69.	2.1	13
144	Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. Journal of Thrombosis and Haemostasis, 2010, 8, 1926-1932.	1.9	35

#	Article	IF	Citations
145	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Thrombosis and Haemostasis, 2010, 104, 118-121.	1.8	34
146	Preface. Hematology/Oncology Clinics of North America, 2010, 24, xiii-xiv.	0.9	1
147	Antiphospholipid Syndrome: A Challenging Hypercoagulable State with Systemic Manifestations. Hematology/Oncology Clinics of North America, 2010, 24, 669-676.	0.9	3
148	The â€œparallel-cohort RCTâ€• Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemporary Clinical Trials, 2010, 31, 131-133.	0.8	25
149	Symposium 4: Hot topics in parenteral nutrition A review of the use of glutamine supplementation in the nutritional support of patients undergoing bone-marrow transplantation and traditional cancer therapy. Proceedings of the Nutrition Society, 2009, 68, 269-273.	0.4	12
150	Severe Hemolytic Anemia Postâ€"Renal Transplantation Produced by Donor Anti-D Passenger Lymphocytes: Case Report and Literature Review. Transfusion Medicine Reviews, 2009, 23, 155-159.	0.9	37
151	Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review. Journal of Critical Care, 2009, 24, 197-205.	1.0	45
152	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. American Journal of Hematology, 2009, 84, 584-588.	2.0	56
153	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. American Journal of Hematology, 2009, 84, 579-583.	2.0	28
154	Definition of major bleeding used by US anticoagulation clinics. Thrombosis Research, 2009, 124, 239-240.	0.8	5
155	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. Thrombosis Research, 2009, 123, 687-696.	0.8	300
156	Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. Expert Review of Hematology, 2009, 2, 357-360.	1.0	1
157	Predicting Deep Venous Thrombosis in Pregnancy: Out in â€œLEFtâ€•Field?. Annals of Internal Medicine, 2009, 151, 85.	2.0	109
158	2009 evidence-based clinical practice guidelines for diagnosing a first episode of lower extremities deep vein thrombosis in ambulatory outpatients. , 2009, 119, 541-9.		1
159	The clinical consequence of subtherapeutic anticoagulation: the low INR study (LINeRS). Journal of Thrombosis and Thrombolysis, 2008, 25, 127-128.	1.0	0
160	Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. Journal of Thrombosis and Thrombolysis, 2008, 25, 96-96.	1.0	2
161	Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 705-706.	0.4	67
162	Preventing and managing bleeding complications in anticoagulated patients: A case based approach. Thrombosis Research, 2008, 123, S42-S45.	0.8	0

#	Article	IF	Citations
163	Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin prophylaxis: prevalence, incidence and risk factors. Critical Care, 2008, 12, R32.	2.5	68
164	Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin<subtitle>An Assessment of Safety and Pharmacodynamics: The DIRECT Study</subtitle>. Archives of Internal Medicine, 2008, 168, 1805.	4.3	133
165	Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. Cmaj, 2008, 179, 417-426.	0.9	484
166	Pharmacology and Management of the Vitamin K Antagonists. Chest, 2008, 133, 160S-198S.	0.4	1,926
167	Combined Aspirinâ€"Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease. Archives of Internal Medicine, 2007, 167, 117.	4.3	172
168	A Red Blood Cell Agglutination <scp>d</scp>-Dimer Test to Exclude Deep Venous Thrombosis in Pregnancy. Annals of Internal Medicine, 2007, 147, 165.	2.0	119
169	The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy. Journal of the American College of Cardiology, 2006, 47, 804-808.	1.2	81
170	The metabolic syndrome and the risk of venous thrombosis: a caseâ€"control study. Journal of Thrombosis and Haemostasis, 2006, 4, 1914-1918.	1.9	144
171	Treatment of Antiphospholipid Antibody Syndromeâ€"Reply. JAMA - Journal of the American Medical Association, 2006, 296, 42.	3.8	2
172	The Management of Anticoagulated Patients Requiring Dental Extraction: A Cross-Sectional Survey of Oral Surgeons and Hematologists.. Blood, 2006, 108, 629-629.	0.6	0
173	Use of Therapeutic Dose Low Molecular Weight Heparin in Patients with Renal Insufficiency: Analysis of Anti-Xa Levels and Creatinine Clearance.. Blood, 2006, 108, 884-884.	0.6	0
174	Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Critical Care Medicine, 2005, 33, 1565-1571.	0.4	957
175	Warfarin Maintenance Dosing Patterns in Clinical Practice. Chest, 2005, 127, 2049-2056.	0.4	197
176	Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. British Journal of Haematology, 2005, 129, 803-810.	1.2	84
177	Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. Intensive Care Medicine, 2005, 31, 48-55.	3.9	60
178	Systematic Overview of Warfarin and Its Drug and Food Interactions. Archives of Internal Medicine, 2005, 165, 1095.	4.3	931
179	A Randomized Trial Comparing 1 mg of Oral Vitamin K With No Treatment in the Management of Warfarin-Associated Coagulopathy in Patients With Mechanical Heart Valves. Journal of the American College of Cardiology, 2005, 46, 732-733.	1.2	38
180	The Safety of Co-Administered Low-Molecular-Weight Heparin and Continuous Epidural Analgesia after Major Orthopedic Surgery: Assessment of a Standardized Management Protocol.. Blood, 2004, 104, 704-704.	0.6	5

#	Article	IF	Citations
181	New anticoagulants: an update. Clinical Advances in Hematology and Oncology, 2004, 2, 743-9.	0.3	0
182	A Diagnostic Strategy Involving a Quantitative Latex <scp>d</scp>-Dimer Assay Reliably Excludes Deep Venous Thrombosis. Annals of Internal Medicine, 2003, 138, 787.	2.0	120
183	Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and <scp>d</scp>-dimer Testing. Annals of Internal Medicine, 2001, 135, 108.	2.0	179
184	Prevention of venous thromboembolism in critically ill surgery patients: A cross-sectional study. Journal of Critical Care, 2001, 16, 161-166.	1.0	30
185	Venous thromboembolic disease: An observational study in medical-surgical intensive care unit patients. Journal of Critical Care, 2000, 15, 127-132.	1.0	114